10x1000 Launches “Flex” Fintech Program with Partners Worldwide to Bridge Global Digital Skills Gap and Drive Financial Inclusion
Fintech training platform 10x1000 Tech for Inclusion announced that it will deepen its collaborations with partners worldwide, working with leading global organizations, tech investors, and industry organizations to offer a program that enables aspiring practitioners to learn from global experts at their own pace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915006200/en/
(Graphic: Business Wire)
Available from October through grants to over 1,000 learners, the Fintech Foundation Program Flex is a fully online certificate program providing practitioners with the mindset, knowledge and skills to become drivers of digital economic growth, according to 10x1000, a global and philanthropic fintech training initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
Flex learners will be recruited through partners such as the IFC (including the SME Finance Forum), United Nations Economic Commission for Africa, Dubai International Financial Centre, Malaysia Digital Economy Corporation, KPMG and fintech associations from Hong Kong, Malaysia, the Philippines, Thailand, and Singapore. (See table for a full list of 10X1000 partners)
“We are delighted to join hands with global partners to bring the 10x1000 training platform to learners worldwide, as we seek innovative approaches to meeting a common goal of bridging the digital skills gap, particularly in communities that need it the most,” said Eric Jing, Chairman and CEO of Ant Group, owner and operator of digital payments platform Alipay. “I am excited that learners from 10x1000’s new Flex program will gain the fintech knowledge they need to support their communities, and help bring us closer to meeting the UN Sustainable Development Goals (SDGs).”
“IFC has been a steadfast supporter of digital innovations that foster financial inclusion. As nations emerge from the Covid-19 pandemic, the world is in need of more visionary fintech leaders to drive such innovation and expand financial access,” said Qamar Saleem, Regional Manager for Advisory Services, Financial Institutions Group, Asia and Pacific, IFC. “We believe 10x1000’s Flex program will bring distinct value to complement existing educational resources with a flexible curriculum that draws on practical experience of leading fintech practitioners across regions.”
Through eight recorded video lectures, attendees of the new Flex program will hear directly from tech entrepreneurs, senior leaders at Ant and other fintech firms as well as distinguished scholars, sharing their first-hand knowledge on topics ranging from ‘the tech behind fintech’ and best practices in leveraging technology to solve real business problems.
Training content provided by 10x1000 is being guided by a Curriculum Steering Committee (CSC), an advisory body responsible for ensuring the quality and effectiveness of the curriculum. The current committee is composed of global experts from industry, academia, and international financial institutions.
Going forward, 10x1000 will also work with partners and alumni to cultivate a global fintech community, creating a vibrant platform that provides opportunities for willing organizations and individuals to contribute to global financial inclusion.
About 10x1000
10x1000 Tech for Inclusion is an open and global fintech training platform that enables learners to become drivers of digital economic growth. Its mission is to train 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
** 10x1000 Tech for Inclusion Partners List **
Founding Partners
1. Alipay (Alipay)
2. IFC (International Finance Corporation)
Global Organizations
1. UNECA (United Nations Economic Commission for Africa)
2. UNWFP (United Nations World Food Programme)
3. SME Finance Forum (SME Finance Forum, Managed by the IFC)
Regional-Country Industry Organizations
1. Africa’s Business Heroes (ABH)
2. DIFC (Dubai International Financial Centre)
3. FTAHK (FinTech Association of Hong Kong)
4. FAOM (FinTech Association of Malaysia)
5. Fintech Alliance PH Inc (Fintech Alliance.ph)
6. MDEC (Malaysia Digital Economy Corporation)
7. MFTA (MENA Fintech Association)
8. SFA (Singapore FinTech Association)
9. SLT (She Loves Tech)
10. TFA (Thai Fintech Association)
Professional Services/Investors
1. BAce Capital (BAce Capital)
2. Gobi Partners (Gobi Partners)
3. KPMG (KPMG)
4. 917Ventures (917Ventures)
** 10x1000 Curriculum Steering Committee Members (2021) **
Nafez Dakkak
Executive Chairman, Edraak.org
Pooma Kimis
Director, Bernstein Autonomous
Qamar Saleem
Regional Industry Manager Asia & Pacific, Financial Institutions Group at International Finance Corporation (IFC)
Daniel Suen
Head of Strategy, International Education, General Manager, China Education, Wiley
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915006200/en/
Contact information
Media
Daryl Loo, Alipay
looliatliang.dlll@alipay.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom